UMC works closely with the World Health Organization (WHO) and runs the WHO Programme for International Drug Monitoring, but is organisationally and financially independent.
The operations of UMC as a WHO Collaborating Centre are governed by an agreement between WHO Headquarters and the Swedish Government. There is an international board to which WHO and the Swedish Government each appoints three members. The Director of UMC reports to the board.
Since 2010, the Chairman of the board has been Dr Anders Milton, who has held senior positions in many Swedish health-related organisations.
A Strategic Executive Team of senior managers guides the work of UMC on a day-to-day basis.
UMC is independent and self-funded. We finance our operations by selling pharmacovigilance products and services to a range of external bodies, ensuring intellectual and scientific independence, sustainability, and freedom to pursue our vision. We do not receive other funding from external sources, except for specific project grants.